rexahn pharmaceuticals

Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the appointment of Peter Brandt and Richard Kivel to the company's board of directors. “Peter and Richard are...